{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-044043","form_type":"8-K","ticker":"TBPH","cik":"0001583107","company_name":"Theravance Biopharma, Inc.","filed_at":"2023-04-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.512641+00:00","generated_at":"2026-06-17T03:38:24.482864+00:00","sec_items":["5.02","8.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Theravance Biopharma appoints James C. Kelly as Class I director","bullets":["James C. Kelly appointed to Board on April 11, 2023, as Class I director through 2024 AGM.","Kelly is Managing Director at Weiss Asset Management, joined in 2010.","He waived equity component of director compensation; standard indemnification agreement in place.","Board size increased to 10, will revert to 9 after Annual Meeting; Kelly deemed independent.","As of March 6, 2023, Kelly beneficially owned 0 ordinary shares of Theravance Biopharma."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-044043","json":"https://secwatch.observer/filing/0001104659-23-044043.json","markdown":"https://secwatch.observer/filing/0001104659-23-044043.md","text":"https://secwatch.observer/filing/0001104659-23-044043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583107/000110465923044043/0001104659-23-044043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583107/000110465923044043/tm2312299d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T03:38:24.482864+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0cf58bb137","claim":"James C. Kelly was appointed as Class I member of the Board at Theravance Biopharma, Inc..","evidence_excerpt":"On April 11, 2023, James C. Kelly was appointed by the Board of Directors (the “Board”) of Theravance Biopharma, Inc. (the “Company”) to serve as a Class I member of the Board for a term expiring at the Company’s Annual General Meeting of Shareholders in 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583107/000110465923044043/0001104659-23-044043-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I member of the Board"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}